Rezorba in treatment of metastatic prostate cancer bone lesions

Kaprin A.D., Sivkov A.V., Oschepkov V.N., Gafanov R.A., Keshishev N.G.

The main aim of the work described in this article is efficiency and safety estimation of Rezorba (zoledronic acid) in prostate cancer patients with bone metastasies (MTS). This drug suppresses osteoclast activity, does not render undesirable influence on formation, mineralization and mechanical properties of bone tissue, possesses the direct antineoplastic activity, which is efficient in metastatic disease.

Sixty patients were included in research with MTS prostate cancer. Thirty six patients underwent bilaterial orchiectomy, 24 received medicamentous castration. All patients had antiandrogenic therapy at initial stages, one patient underwent prostatectomy, 18 patients received chemotherapy (taxoter+praednisolon). Rezorba was administered in an outpatient clinic, 4 mg I.V. 1 time in 3-4 weeks. During the treatment alkaline phosphatase, blood calcium, and pain syndrome level were analyzed.

The results prove that Rezorba is effective and safe drug from the bisphosphonate group. Treatment is convenient for patients. Positive dynamics of alkaline phoshatase level and gradual decrease in level of blood calcium is noted. The drug quickly stops the pain syndrome, provides effective protection of bone tissue, suppresses bone destruction and promotes their regeneration, improving QoL in patients with MTS hormoneresistant prostate cancer. In combination with antineoplastic therapy, the drug has a good tolerance level, and does not concede to import analogues by efficiency and safety.

Rezorba should take important place in combination therapy of the prostate cancer patients with bone MTS.